The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA.
 
Roy S. Herbst
Leadership - Jun Shi Pharmaceuticals
Consulting or Advisory Role - Abbvie; ARMO Biosciences; AstraZeneca; Biodesix; Bolt Biotherapeutics; Bristol-Myers Squibb?; EMD Serono; Genentech/Roche; Genmab; Halozyme; Heat Biologics; IMAB Biopharma; Immunocore; Infinity Pharmaceuticals; Jun Shi Pharmaceuticals; Lilly; Loxo; Merck; Midas Health Analytics; Mirati Therapeutics; Nektar; Neon Therapeutics; NextCure; Novartis; Pfizer; Sanofi; Seattle Genetics; Shire; Spectrum Pharmaceuticals; Symphogen; Takeda; TESARO; Tocagen
Research Funding - AstraZeneca; Genentech/Roche; Lilly; Merck
 
Masahiro Tsuboi
Honoraria - AstraZeneca KK,; Bristol-Myers Squibb Japan; Chugai Pharma; Johnson & Johnson; Medtronic Japan; MSD K.K; Novartis Pharmaceuticlas Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Teijin Pharma
Research Funding - Boehringer-Ingelheim Japan (Inst); Merck (Inst)
 
Thomas John
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Ignita; Merck; MSD; Pfizer; Roche; Specialised Therapeutics; Takeda
 
Christian Grohé
Honoraria - AstraZeneca; Boehringer Ingelheim; Lilly; MSD Oncology; Novartis; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; MSD Oncology
Research Funding - AstraZeneca (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Bristol-Myers Squibb; Roche
 
Margarita Majem
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Helsinn Therapeutics; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Takeda; Tesaro
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Roche
 
Jonathan Wade Goldman
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech/Roche; Lilly; Trovagene; Vortex Biosciences
Speakers' Bureau - Merck
Research Funding - Abbvie; Array BioPharma; Astellas Pharma; Astex Pharmaceuticals; AstraZeneca/MedImmune; Bristol-Myers Squibb; Celgene; Clovis Oncology; Corvus Pharmaceuticals; Genentech/Roche; Lilly; Spectrum Pharmaceuticals; Threshold Pharmaceuticals
 
Sang-We Kim
No Relationships to Disclose
 
Dominika Marmol
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Yuri Rukazenkov
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Yi-Long Wu
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb/China; Lilly; MSD Oncology; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Roche
Research Funding - Boehringer Ingelheim (Inst); Pfizer (Inst); Roche (Inst)